Vivek Ramaswamy (Jeff Rumans/JPM 2020)
Urovant's lead drug disappoints in mid-stage study as first big FDA decision looms
Just as Urovant gets ready for its first big FDA decision on vibegron, the drug has flopped in what would’ve been a follow-on indication. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
